US FDA grants IPI-549 in combination with nivolumab Fast Track Designation for the treatment of advanced urothelial cancer

IPI-549 is a first-in-class oral medicine that selectively inhibits PI3K-gamma. It is currently being investigated in the global Phase II MARIO-275 study, in combination with nivolumab, in the treatment of patients with platinum-refractory advanced urothelial cancer.


Biospace Inc.